NAMS · NewAmsterdam Pharma Company NV
United States · RS rating 19 · As of 2026-11-03
| Price | 19.90 USD |
|---|---|
| 1-day change | +1.7% |
| RS rating (overall / 1M / 3M / 12M) | 19 / 31 / 23 / 23 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 20 / 7 / 9 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -36.3% |
| Sales growth Q/Q | -90.8% |
| Distance from 52-week high | +52.0% |
| Market cap (USD) | $3.6B |